← FDA WARNING LETTERS
FDA WARNING LETTER22 February 2022

CytoDyn, Inc. — FDA Warning Letter

New Drug/Labeling/Misbranded

Company
CytoDyn, Inc.
Letter date
22 February 2022
Issuing office
The Office of Prescription Drug Promotion (OPDP)
READ THE FULL LETTER

The complete warning letter, including every cited observation, is published by the FDA. SPEQ surfaces and indexes it for reference — the authoritative text lives on fda.gov.

View on fda.gov →
DON’T BE THE NEXT LETTER
Assess your quality systemBaseline against 12 GxP domains in 10 minutes →Decode the standardsThe requirements behind the citations →All warning lettersBrowse the live FDA feed →

Warning-letter details are published by the U.S. FDA; SPEQ surfaces them for reference and is not affiliated with or endorsed by the FDA. The authoritative text is on fda.gov.